Acquired

Erydel Stock

Erydel develops technology for drug delivery of pharmacological agents through red blood cells.

Sign up today and learn more about Erydel Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Erydel Stock

Based in Urbino, EryDel has developed and patented a technology for drug delivery of pharmacological agents through erythrocytes (red blood cells). This process allow to easily load red blood cells with drugs, proteins, contrasting agents for diagnostic purposes, nanoparticles etc. that can be progressively released into the patient body thus allowing an increased efficacy of the therapy and a reduction of collateral effects. The benefit is extremely significant particularly for chronic pathologies that requires continuous daily treatments for patients which could be substituted by monthly transfusion of blood loaded with specific therapeutic agents. Currently, the solution has been tested by several patients for the treatment of Inflammatory Bowel Diseases (IBDs) such as ulcer colitis and Crohn disease. The company can provide a complete support for the drug delivery process including a specific device for the erythrocytes loading ("Red Cell Loader"), and disposable kits.

Funding History

December 2008$2.5M
July 2013$15.0M
April 2018$26.5M

Management

Chief Executive Officer and Board Member

Luca Benatti

Founder & CSO

Mauro Magnani

CMO

Guenter R. Janhofer

COO

Giovanni Mambrini

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo